Differential modulation of cytokine production by drugs: Implications for therapy in heart failure

Journal of Molecular and Cellular Cardiology

Volumn 28, Issue 12, 1996, Pages 2491-2499

  Matsumori, Akira ^a   Ono, Koh ^b   Sato, Yukihito ^b   Shioi, Tetsuo ^b   Nose, Yoshisuke ^b   Sasayama, Shigetake ^b  

^a KYOTO UNIVERSITY   (Japan)

^b NONE

Author keywords

Amrinone; Interleukin 1; Interleukin 6; Phosphodiesterase inhibitor; Pimobendan; Tumor necrosis factor; Vesnarinone

Indexed keywords

1 [6 CHLORO 4 (3,4 METHYLENEDIOXYBENZYLAMINO) 2 QUINAZOLINYL] 4 PIPERIDINECARBOXYLIC ACID; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 8 BROMO CYCLIC AMP; 8 BROMO CYCLIC GMP; AMRINONE; CYCLIC AMP; CYCLIC GMP; CYTOKINE; INOTROPIC AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PIMOBENDAN; PIPERANOMETOZINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; HEART FUNCTION; HEMODYNAMICS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOMODULATION; LONG TERM CARE; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL; SURVIVAL;

EID: 0030448882     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1996.0241     Document Type: Article

References (46)

1. DINARELLO CA, 1988. Biology of interleukin 1. FASEB J 2: 108-115.
2. ESSAYAN DM, HUANG S-K, UNDEM BJ, KAGEY-SOBOTKA A, LICHTENSTEIN LM, 1994. Modulation of antigen-and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 153: 3408-3416.
3. EVANS HG, LEWIS MJ, SHAR AM, 1993. Interleukin-1β modulates myocardial contraction via dexamethasone-sensitive production of nitric oxide. Cardiovasc Res 27: 1486-1490.
4. FELDMAN AM, BRISTOW MR, PARMLEY WW, CARSON PE, PEPINE CJ, GILBERT EM, STROBECK JE, HENDRIX GH, POWERS ER, BAIN RP, WHITE BG, 1993. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 329: 149-155.
5. + currents in cytotoxic T lymphocytes. Circ Res 78: 253-261.
6. FINKEL MS, ODDIS CV, JACOB TD, WATKINS SC, HATTLER BG, SIMMONS RL, 1992. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257: 387-389.
7. GALLIN EK, 1991. Ion channels in leukocytes. Pharmacol Rev 71: 775-811.
8. 2 and cyclic GMP. Immunobiol 182: 44-55.
9. HEGEWISCH S, WEH H-J, HOSSEELD DK, 1990. TNF-induced cardiomyopathy. Lancet 335: 294-295.
10. HIDAKA H, ENDO T, 1984. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase-basic and potential clinical applications. In: Strada SJ, Thompson WJ, eds, Advances in Cyclic Nucleotide Protein Phosphorylation Research (Vol. 16). New York, Raven Press, 245-259.
11. HIROTA H, YOSHIDA K, KISHIMOTO T, TAGA T, 1995. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 92: 4862-4866.
12. HOCKING DC, PHILLIPS PG, FERRO TJ, JOHNSON A, 1990. Mechanisms of pulmonary edema induced by tumor necrosis factor-α Circ Res 67: 68-77.
13. HOSENPUD JD, CAMPBELL SM, MENDELSON DJ, 1989. Interleukin-1-induced myocardial depression in an isolated beating heart preparation. J Heart Transplant 8: 460-464.
14. HURME M, 1990. Modulation of interleukin-1 β production by cyclic AMP in human monocytes. FEBS Lett 263: 35-37.
15. IIJIMA T, TAIRA N, 1987. Membrane current changes responsible for the positive inotropic effect of OPC 8212, a new positive inotropic agent, in single cells of the guinea pig heart. J Pharmacol Exp Ther 240: 657-662.
16. KATZ AM, 1994. The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Int Med 121: 363-371.
17. KAUFFMAN RF, CROWE VG, UTTERBACK BG, ROBERTSON DW, 1986. LY195115: A potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcomplasmic reticulum. Mol Pharmacol 30: 609-616.
18. KAUFFMAN RF, SCHENCK KW, UTTERBACK BG, CROWE VG, COHEN ML, 1987. In vitro vascular relaxation by new inotropic agents: Relationship to phosphodiesterase inhibition and cyclic nucleotides. J Pharmacol Exp Ther 242: 864-872.
19. KODAMA K, ADACHI H, MORI N, SAITO I, 1994. Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs. Eur J Pharmacol 263: 93-99.
20. KUBO SH, GOLLUB S, BOURGE R, RAHKO P, COBB F, JESSUP M, BROZENA S, BRODSKY M, KIRLIN P, SHANES J, KONSTAM M, GRADMAN A, MORLEDGE J, CINQUEGRANI M, SINGH S, LEJEMTEL T, NICKLAS J, TROHA J, COHN JN, for the Pimobendan Multicenter Research Group, 1992. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Circulation 85: 942-949.
21. + channels depolarize human T lymphocytes: mechanism of anti-proliferative effect of charybdotoxin. Proc Natl Acad Sci USA 89: 10094-10098.
22. LEVINE B, KALMAN J, MAYER L, FILLIT HM, PACKER M, 1990. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323: 236-241.
23. LEWIS RS, CAHALAN MD, 1990. Ion channels and signal transduction in lymphocytes. Annu Rev Physiol 52: 415-430.
24. MANGANIELLO VC, 1987. Subcellular localization and biological function of specific cyclic nucleotide phosphodiesterases. J Mol Cell Cardiol 19: 1037-1040.
25. MANN DL, YOUNG JB, 1994. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 105: 897-904.
26. MATSUI S, MATSUMORI A, MATOBA Y, UCHIDA A, SASAYAMA S, 1994. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone: suppression of natural killer cell activity and tumor necrosis factor-α production. J Clin Invest 94: 1212-1217.
27. MATSUMORI A, SHIOI T, YAMADA T, MATSUI S, SASAYAMA S, 1994a. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 89: 955-958.
28. MATSUMORI A, YAMADA T, SUZUKI H, MATOBA Y, SASAYAMA S, 1994b. Increased circulating cytokines in patients with cardiomyopathy and myocarditis. Br Heart J 72: 561-566.
29. MOLNAR-KlMBER K, YONNO L, HEASLIP R, WEICHMAN B, 1993. Modulation of TNF-α and IL-1β from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions 39: C77-C79.
30. NICHOLSON CD, CHALLISS RAJ, SHAHID M, 1991. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 12: 19-27.
31. OPC-8212 Multicenter-Research Group, 1990. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardiovasc Drugs Ther 4: 419-426.
32. PACKER M, 1993. The development of positive inotropic agents for chronic heart failure: How have we gone astray? J Am Coll Cardiol 22: 119A-126A.
33. PESTKA S, LANGER JA, ZOON KC, SAMUEL CE, 1987. Interferons and their actions. Ann Rev Biochem 56: 727-777.
34. PINSKY DJ, CAI B, YANG X, RODRIGUEZ C, SCIACCA RR, CANNON PJ, 1995. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor β. J Clin Invest 95: 677-685.
35. REEVES ML, LEIGH BK, ENGLAND PJ, 1987. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Biochem J 241: 535-541.
36. RITZ J, SCHMIDT RE, MICHON J, HERCEND T, SCHLOSSMAN SF, 1988. Characterization of functional surface structures on human natural killer cells. Adv Immunol 42: 181-211.
37. SASAYAMA S, 1992. What do the newer inotropic drugs have to offer? Cardiovasc Drugs Ther 6: 15-18.
38. SASAYAMA S, ASANOI H, KIHARA Y, YOKAWA S, TERADA Y, YOSHIDA S, EJIRI M, HORIKOSHI I, 1994. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. Heart Vessels 9: 113-120.
39. SERKKOLA E, HURME M, PALKAMA T, 1992. Prolonged elevation of intracellular cyclic AMP activated interleukin-1 production of human peripheral blood monocytes. Scand J Immunol 35: 203-208.
40. SHAHID M, NICHOLSON CD, 1990. Comparison of cyclic nucleotide phosphodiesterase isoenzyme in rat and rabbit ventricular myocardium: Positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrin one and rolipram. Naunyn-Schmiedeberg's Arch Pharmacol 342: 698-705.
41. SHIOI T, MATSUMORI A, MATSUI S, SASAYAMA S, 1994. Inhibition of cytokine production by a new inotropic agent, vesnarin one, in human lymphocytes, T cell line, and monocytic cell line. Life Sci 54: PL11-PL16.
42. SIMPSON AWM, REEVES ML, RINK TJ, 1988. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets. Biochem Pharmacol 37: 2315-2320.
43. THAIK CM, CALDERONE A, TAKAHASHI N, COLUCCI WS, 1995. Interleukin-1β modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 96: 1093-1099.
44. WEISENSEE D, BEREITER-HAHN J, SCHOEPPE W, FRIEDRICH LW, 1993. Effects of cytokines on the contractility of cultured cardiac myocytes. Int J Immunopharmacol 15: 581-587.
45. WEISHAAR RE, KOBYLARZ-SINGER DC, STEFFEN RP, KAPLAN HR, 1987. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating contractility. Circ Res 61: 539-547.
46. WOODLEY SL, MCMILLAN M, SHELBY J, LYNCH DH, ROBERTS LK, ENSLEY RD, BARRY WH, 1991. Myocyte injury and contraction abnormalities produced by cytotoxic T lymphocytes. Circulation 83: 1410-1418.